Skip to main content

Table 2 Logistic regression of predictors for MRA initiation by cohort in the CKD population

From: Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study

Independent variables CKD DKD CKD + HF DKD + HF
Odds ratio Confidence interval P value Odds ratio Confidence interval P value Odds ratio Confidence interval P value Odds ratio Confidence interval P value
Lower limit Upper limit Lower limit Upper limit Lower limit Upper limit Lower limit Upper limit
Age, years (vs 18–34 years)
 35–44 1.93 1.43 2.61 < 0.0001 1.15 0.72 1.82 0.5666 0.82 0.50 1.34 0.4255 1.10 0.47 2.53 0.83
 45–54 1.48 1.11 1.96 0.0075 1.01 0.66 1.55 0.9672 0.98 0.64 1.51 0.9423 1.31 0.60 2.85 0.50
 55–64 1.31 0.99 1.73 0.0593 0.90 0.59 1.37 0.6131 0.70 0.46 1.06 0.0897 1.14 0.53 2.48 0.73
 65+ 0.95 0.71 1.27 0.7419 0.63 0.41 0.98 0.0381 0.40 0.27 0.61 < 0.0001 0.80 0.37 1.74 0.58
Sex (vs male)
 Female 1.43 1.28 1.59 < 0.0001 1.04 0.93 1.16 0.4554 0.77 0.66 0.89 0.0004 0.83 0.73 0.93 0.002
Prescribing physician specialty at inclusion (vs general/family practice)
 Internal Medicine 1.04 0.86 1.26 0.695 1.25 1.03 1.52 0.0266 1.03 0.77 1.39 0.8268 1.30 1.02 1.66 0.03
 Cardiology 1.28 0.93 1.75 0.126 1.11 0.78 1.59 0.5677 1.36 0.97 1.92 0.0789 1.79 1.34 2.40 < 0.0001
 Nephrology 1.45 1.22 1.73 < 0.0001 1.76 1.47 2.10 < 0.0001 1.27 0.95 1.70 0.1068 1.11 0.88 1.41 0.38
 Hospital 1.69 1.38 2.07 < 0.0001 1.49 1.21 1.85 0.0002 2.09 1.61 2.73 < 0.0001 1.68 1.34 2.11 < 0.0001
Other/unknown 1.34 1.12 1.601 0.0017 1.24 1.02 1.51 0.0288 1.50 1.15 1.95 0.0027 1.30 1.03 1.63 0.02
Previous medication use (yes vs no)
 ARBs 1.75 1.55 1.97 < 0.0001 1.62 1.44 1.82 < 0.0001 1.40 1.19 1.65 < 0.0001 1.34 1.18 1.52 < 0.0001
 ACE inhibitors 1.24 1.10 1.39 0.0003 1.37 1.22 1.54 < 0.0001 1.33 1.16 1.54 < 0.0001 1.34 1.19 1.51 < 0.0001
 Renin inhibitors 2.11 1.44 3.10 0.0001 1.66 1.21 2.27 0.0016 1.28 0.65 2.52 0.476 1.25 0.83 1.890 0.28
 Vasodilators 2.20 1.92 2.53 < 0.0001 1.64 1.45 1.86 < 0.0001 1.25 1.06 1.46 0.0066 0.97 0.85 1.09 0.59
Comorbidities
 LVH 1.26 0.97 1.65 0.0884 1.71 1.39 2.09 < 0.0001 1.71 1.46 2.000 < 0.0001 1.28 1.11 1.46 0.0005
 Anemia 1.07 0.94 1.21 0.2916 0.84 0.74 0.95 0.0063 0.72 0.62 0.84 < 0.0001 0.70 0.62 0.79 < 0.0001
 Edema 2.14 1.85 2.47 < 0.0001 2.09 1.83 2.38 < 0.0001 1.48 1.26 1.73 < 0.0001 1.47 1.30 1.66 < 0.0001
 Proteinuria 1.18 1.00 1.41 0.0571 1.31 1.13 1.51 0.0004 0.82 0.59 1.15 0.2475 0.98 0.80 1.20 0.85
 Hyperkalemia 0.96 0.71 1.30 0.8046 0.55 0.42 0.73 < 0.0001 0.49 0.34 0.70 0.0001 0.57 0.45 0.71 < 0.0001
 Sensitivity testing: c-statistic 0.67 0.66 0.68 0.63
  1. ACE acetylcholinesterase, ARB angiotensin II receptor blocker, CKD chronic kidney disease, DKD diabetic kidney disease, HF heart failure, LVH left ventricular hypertrophy, MRA mineralocorticoid receptor antagonist